Kárpati Krisztián, Brandtmüller Agnes, Májer István, Gulácsi László
Budapesti Corvinus Egyetem, Közszolgálati Tanszék, Egészség-gazdaságtani.
Acta Pharm Hung. 2006;76(4):191-9.
In our research we assessed the drug reimbursement of the National Health Insurance Fund Administration (NHIFA) in different ATC groups. We used the aggregated data of retail pharmacies in 2004, analysing separately the accentuated and elevated categories associated with medical indications. According to the 2004 data it was the drugs for cardiovascular; endocrine and metabolic disorders affecting the largest population and making the highest proportion of the total reimbursement. In addition, the turnover of some drugs for mental disorders was also significant. As for the number of patients in the cancer group it is much smaller, but as a result of the huge costs of their therapies these belong to the highest reimbursed categories as well. Without the special, separately financed category the annual drug subsidy was 257 bill. HUF, which totalled 423 bill. HUF on consumer price. The reimbursement of the NHIFA in the top 25 categories exceeded 177 bill. HUF. In the accentuated category the contribution of the NHIFA approximated 49 bill. HUF spent on the treatment of cancer, diabetic and some psychiatric disorders. In the elevated category based on health status the products of mental, digestive, bone and respiratory systems disorders were responsible for the highest turnover with more than 55 bill. HUF subsidy. Besides knowing the amount of reimbursement it is also important to be familiar with the size of affected, treated population. However in many cases we do not have any detailed, up-to-date Hungarian data, so the under-, or the possible overtreatment can hardly be analysed accurately.
在我们的研究中，我们评估了国家健康保险基金管理局（NHIFA）在不同解剖治疗学分类（ATC）组中的药品报销情况。我们使用了2004年零售药店的汇总数据，分别分析了与医学适应症相关的突出和高发类别。根据2004年的数据，治疗心血管、内分泌和代谢紊乱的药物影响的人群最多，在总报销中所占比例最高。此外，一些治疗精神障碍的药物营业额也很高。至于癌症组的患者人数则少得多，但由于其治疗费用高昂，这些药物也属于报销最高的类别。如果没有特别的、单独资助的类别，年度药品补贴为2570亿匈牙利福林，按消费价格计算总计4230亿匈牙利福林。NHIFA在排名前25的类别中的报销超过1770亿匈牙利福林。在突出类别中，NHIFA的贡献约为490亿匈牙利福林，用于治疗癌症、糖尿病和一些精神疾病。在基于健康状况的高发类别中，精神、消化、骨骼和呼吸系统疾病的产品营业额最高，补贴超过550亿匈牙利福林。除了了解报销金额外，熟悉受影响、接受治疗的人群规模也很重要。然而，在许多情况下，我们没有任何详细的、最新的匈牙利数据，因此很难准确分析治疗不足或可能的过度治疗情况。
